Xeris Biopharma Holdings, Inc./$XERS
1D1W1MYTD1Y5YMAX
Capital at risk
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
- Ticker
- $XERS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 435
- Headquarters
- Chicago, United States
- Website
- www.xerispharma.com
XERS Metrics
BasicAdvanced
$1.4B
-
-$0.10
0.85
-
Price and volume
Market cap
$1.4B
Beta
0.85
52-week high
$10.08
52-week low
$5.25
Average daily volume
1.7M
Financial strength
Current ratio
1.449
Quick ratio
0.949
Long term debt to equity
-22.534
Total debt to equity
-29.735
Interest coverage (TTM)
0.85%
Profitability
EBITDA (TTM)
48.769
Gross margin (TTM)
86.58%
Net profit margin (TTM)
-5.12%
Operating margin (TTM)
10.91%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
6.13%
Return on equity (TTM)
118.22%
Valuation
Price to revenue (TTM)
3.738
Price to book
-132.86
Price to tangible book (TTM)
-11.79
Price to free cash flow (TTM)
22.52
Free cash flow yield (TTM)
4.44%
Free cash flow per share (TTM)
0.331
Growth
Revenue change (TTM)
36.33%
Earnings per share change (TTM)
-51.36%
3-year revenue growth (CAGR)
35.75%
3-year earnings per share growth (CAGR)
-42.00%
Upcoming events
No upcoming events
XERS News
AllArticlesVideos
Funds containing XERS
AllUSDGBPEUR
Fund name | Fund size | $XERS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.